Hope Biosciences has been cleared by the FDA to go ahead with a phase 2 trial to assess its investigational stem cell therapy in bringing immune support against COVID-19.
With this, Hope Biosciences will be assessing the safety and efficiency of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial.
The clinical-stage biotechnology company alleges that based on demand, its core technology can produce high-quality, fully characterized, fresh mesenchymal stem cells.
The company states that mesenchymal stem cells are regarded for their immunomodulatory and regenerative potential. The company added that in phase I/II of clinical trials for rheumatoid arthritis, results showed that HB-adMSCs were safe and effective in limiting systemic inflammation.
Hope Biosciences president and CEO Donna Chang says that the company expects that giving HB-adMSC therapies will boost the immune system especially in cases of persons at high risk of developing COVID-19.
She adds that a healthy immune system is more capable to defend against infectious agents like SARS-CoV-2 and decreases the chance a patient will become critically ill which not only helps keep people healthy, but also limits the tremendous burden currently on stressed healthcare systems. Further on she adds that with this treatment, they can better protect the more susceptible.